25 Corporate Drive
Suite 360
AlloCure Inc.
There are precious few options for addressing acute kidney injury, a condition that is characterized by a rapid deterioration of kidney function, often occurring in people with certain risk factors and co-morbidities. Some 300,000 to 500,000 people each year in the US suffer from AKI. AlloCure Inc. is developing bone marrow-derived adult stem cells harvested from anonymous donors, and prepared as an off-the-shelf therapy, to prevent and perhaps eventually treat AKI.
More from Cell Therapies
• By
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
• By
The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
More from Advanced Therapies
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.